Janux Therapeutics Inc Total Liabilities
Janux Therapeutics Inc total liabilities. Based on the latest financial reports, Janux Therapeutics Inc (JANX) has total liabilities worth $86.69 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Janux Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Janux Therapeutics Inc (2019–2025)
Total liabilities of Janux Therapeutics Inc from 2019 to 2025. This chart illustrates how Janux Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Janux Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Janux Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Run Long Construction Co Ltd
TW:1808
|
Taiwan | NT$38.39 Billion |
|
Cisen Pharmaceutical Co Ltd
SHG:603367
|
China | CN¥1.41 Billion |
|
Jaya Real Property Tbk
JK:JRPT
|
Indonesia | Rp4.48 Trillion |
|
JM AB (publ)
ST:JM
|
Sweden | Skr15.78 Billion |
|
Henan Jindan Lactic Acid Technology
SHE:300829
|
China | CN¥1.30 Billion |
|
Mirle Automation Corp
TW:2464
|
Taiwan | NT$6.23 Billion |
|
Guangzhou Fangbang Electronics Co Ltd
SHG:688020
|
China | CN¥407.62 Million |
|
Guangzhou Newlife New Material Co. Ltd. A
SHE:301323
|
China | CN¥145.09 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Janux Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Janux Therapeutics Inc assets under control.
Liquidity & Leverage Metrics
Janux Therapeutics Inc Total Liabilities Ratios Explained
Janux Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Janux Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Janux Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of Janux Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $50.70 Million | +30.89% |
| 2024-12-31 | $38.73 Million | +7.42% |
| 2023-12-31 | $36.06 Million | -16.67% |
| 2022-12-31 | $43.27 Million | +220.59% |
| 2021-12-31 | $13.50 Million | -56.26% |
| 2020-12-31 | $30.86 Million | +257.82% |
| 2019-12-31 | $8.62 Million | -- |
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in… Read more